A study by Chiron et al. 2013 [164] suggested that the tumoricidal effect of idelalisib is enhanced by G1-arrest of the cell cycle; therefore, idelalisib should be administered with concomitant inhibition of CDK4/CDK6 to increase the sensitivity of MCL cells to treatment regimen. The gene discussed is CDK4; the disease is mantle cell lymphoma.